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Abstract The prevention of bluetongue is typically achieved
with mono- or polyvalent modified- live-attenuated virus
(MLV) vaccines. MLV vaccines typically elicit a strong anti-
body response that correlates directly with their ability to rep-
licate in the vaccinated animal. They are inexpensive, stimu-
late protective immunity after a single inoculation, and have
been proven effective in preventing clinical bluetongue dis-
ease. In this study, we evaluated the safety, immunogenicity,
and efficacy of a bluetongue vaccine against Bluetongue virus
serotypes 4 and 16 in sheep. All the animals remained clini-
cally healthy during the observation period. The vaccinated
animals showed no clinical signs except fever (>40.8 °C) for
2–4 days. Rapid seroconversion was observed in the sheep,
with the accumulation of high antibody titers in the vaccinated
animals. No animal became ill after the challenge, indicating
that effective protectionwas achieved. Therefore, this vaccine,
prepared from attenuated bluetongue virus strains, is safe, im-
munogenic, and efficacious.
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Introduction
Bluetongue is a viral disease transmitted by Culicoides spp.
Infection is characterized by fever, congestion, edema, hem-
orrhage, hyperemia and ulceration of the oral mucosa,
coronitis, and lameness in domestic and wild ruminants
(Roy 2002). Bluetongue virus (BTV) belongs to the family
Reoviridae and is the type species of the genus Orbivirus,
which also includes the epizootic hemorrhagic disease virus
of deer and African horse sickness virus. BTV has a high level
of antigenic variation, with 27 serotypes recognized world-
wide (Jenckel et al. 2015).
Bluetongue was first described in Africa at the beginning of
the 20th century and was considered exotic in Europe be-
fore1998. Since then, at least six serotypes (BTV-1, -2,
-4, -8, -9, and -16) have invaded the European mainland on
different occasions (Bréard et al. 2011), with a recent epizootic
outbreak. The disease is mainly spread through trading of
breeding animals from bluetongue-enzootic countries
(Murueva 2011). According to data from the Ministry of Ag-
riculture of the Republic of Kazakhstan on beef imports, over
50,000 head of cattle were delivered to Kazakhstan from the
United States, Czech Republic, Canada, Russia, Ukraine,
France, Australia, Ireland, Austria, and Germany in 2011–
2014 (http://kapital.kz/economic/30953/rk-ogranichit-import-
krupnogo-rogatogo-skota.html). Importation creates a risk of
the emergence of bluetongue because many of these countries
have enzootic bluetongue infections (OIE, Terrestrial Animal
Health Code 2011). Over the past 15 years, Kazakhstan has
conducted no serosurveys to monitor BTV infection, although
neighboring countries contain seropositive animals
(Zhugunisov et al. 2009; Vishnyakov et al. 1995) and have
isolated different serotypes of BTV (Avci et al. 2014; Yang
et al. 2011; Yang et al. 2012). Moreover, Lundervold et al.
(2004) found BTV circulating in Kazakhstan among rumi-
nants more than 10 years ago. Therefore, Kazakhstan is at
an unknown, but significant, risk of bluetongue.
Bluetongue is typically prevented with mono- and polyva-
lent modified live virus (MLV) vaccines, inactivated (killed)
virus vaccines, virus-like particles produced from recombi-
nant baculoviruses, or recombinant Vaccinia- or -Canarypox
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virus-vectored vaccines (Savini et al. 2008; Noad and Roy
2009). MLV vaccines typically elicit a strong antibody re-
sponse, which correlates directly with their ability to replicate
in the vaccinated animal. The vaccines are inexpensive,
stimulate protective immunity after a single inoculation,
and have been proven effective in preventing clinical
disease (Savini et al. 2008; Patta et al. 2004).
Given the recent spread of bluetongue to areas
around Kazakhstan and worldwide, there is significant
interest in developing an efficacious and safe vaccine
against BTV serotypes 4 and 16, because these are most
prevalent in the areas surrounding Kazakhstan. No in-
formation is currently available on the duration of the
protective properties of live-attenuated vaccines against
bluetongue. Therefore, in this study, we undertook de-
veloping and testing of an attenuated bivalent vaccine against




We used the BTV strains Khuroson-40/13/4 (BTV-4) and RT/
RIBSP40/13/16 (BTV-16) (Sametova et al. 2013), which were
obtained in lyophilized form from the laboratory of the
BCollection of Microorganisms^ at the Research Institute for
Biological Safety Problems (RIBSP) and refreshed in Vero cells.
Both strains were isolated individually by serial passages in
chicken embryos (to passage 40), then in Vero cell culture (pas-
sage 10). To determine the reversion of the attenuated viruses, the
viral material was passaged in mice (1–3 days of age) and sheep
(6–12 months of age). The sheep and mice remained alive, with
no clinical signs of infection for 30 days. Both animal models,
which are commonly used to evaluate the attenuation of
BTV, are sufficient to test the attenuated strains (Franchi
et al. 2008). By this work, the results of the study are
presented in detail in a previously published paper
(Sametova et al. 2013). We have also obtained patents
for strains Khuroson-40/13/4 (patent #2013/1344.1) and
RT/RIBSP40/13/16 (patent #2013/1345.1) (https://gosreestr.
kazpatent.kz/ru/Search%20Patent). The viral material was
titrated in Vero cell cultures, and the viral titers were
expressed in log10 tissue culture infective doses (TCID)50/
mL, calculated with the method of Reed and Muench (1938).
Animals and bioethics
A total of 288 3–6-month-old female Kazakh fat-tailed sheep
were used in this study. The sheep for the experiments were
kept in quarantine for 1 month holding thermometry, after a
clinical examination and blood serum test for the presence of
specific antibodies, with a competitive enzyme-linked immu-
nosorbent assay (cELISA; ID-Screen Bluetongue Early detec-
tion ELISA, ID-Vet, Montpellier, France). All the sheep were
healthy and seronegative for BTV 3 days before the first vac-
cination. The animals were randomly allocated to the vaccinat-
ed and unvaccinated groups. Each group was kept in a separate
room and had free access to water and feed throughout the
experiment. This study was performed in compliance with na-
tional and international laws and guidelines on animal handling,
and the experimental protocol was approved by the Committee
on the Ethics of Animal Experiments of the RIBSP of the Sci-
ence Committee of the Ministry of Education and Science of
the Republic of Kazakhstan (permit number: 0114/100).
Preparation of the bivalent BTV vaccine
Each viral suspension (Khuroson-40/13/4 and RT/RIBSP40/
13/16 vaccine strains) was clarified by centrifugation at
3000×g for 30 min. Viral suspension was then combined with
a stabilizing medium (at a final concentration of 3 % peptone
[Sigma–Aldrich, St. Louis, MO, USA] and 2 % lactose [Sig-
ma–Aldrich]) in a ratio of 1:1. A total of 200,000 units of
penicillin, 200 mg of streptomycin, and 5000 units of nystatin
were added to the suspension, the volume was expanded to
1 L, and the solution was refrigerated at 4 °C for 10–12 h. The
liquid was then divided into aliquots in 1 mL ampoules and
lyophilized for storage.
Vaccine safety
The safety ofvaccine was tested by injecting it subcuta-
neously to nine sheep at a dose of 106 TCID50/mL. The
paired control group was administered 1 mL of subcu-
taneous phosphate-buffered saline (PBS). After vaccina-
tion, the body temperatures of the sheep were checked
daily and their clinical signs were monitored for 14 days.
The animals that showed severe clinical signs (loss of
more than 20 % body weight, frequent hunching, severe con-
junctivitis, or any condition that prevented food or water in-
take) were euthanized.
Testing for reversion of the vaccine to wild type
We used 30 seronegative sheep to test the seroconversion of
the vaccine. The sheep were divided into 10 groups of three
animals. The first group was administered the vaccine intra-
venously at a dose of 104 TCID50/mL. To detect viremia 7–
8 days after viral inoculation, blood samples were collected
from the febrile animals in ethylenediaminetetraacetic acid.
The blood samples were pooled and titrated in Vero cell cul-
tures. The inoculum (10-mL) was administered to the second
group of three seronegative sheep. Further testing was per-
formed similarly with all 10 passages in three replicates each.
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The animals were observed as described above, for approxi-
mately 3 weeks, to evaluate their health status and viremia.
Vaccine administration
Two hundred forty female sheep were inoculated subcutaneous-
ly with a single dose (104 TCID50/mL) of vaccine. During the
vaccination phase, the sheep were housed indoors in pens and
their health status monitored (rectal temperature and clinical
signs) for 1 year. Blood samples were taken by jugular veni-
puncture at regular intervals (days 7, 14, 21, 28, 90, 180, 270,
and 360 post-vaccination). The sera were tested for antibody
titers with the serum neutralization test (SNT) and ELISAs.
Challenge study
Virulent strains BTV4 and BTV16 (5.5 LD50/mL for BTV4
and BTV16) were used to challenge the sheep. These BTV
strains were isolated from sheep in the Republic of Tajikistan
during monitoring research by the employees of the RIBSP in
2007 (Abduraimov et al. 2009). Both BTV types were plaque
purified three times in Vero cells and their type specificity was
verified with a microneutralization test. The strains had been
passaged three times in sheep. The challenge material
consisted of blood samples collected from BTV4- and
BTV16-infected animals, which were lyophilized and submit-
ted to the RIBSP collection of microorganisms.We used three
vials of control BTV4 and BTV16 strains for the challenge.
All the vials were opened vials with dried blood, dissolved in
PBS, and pooled, separately. The vaccinated sheep (described
above) were intravenously administered 10 mL of homolo-
gous virulent strains (5.5 log10 ELD50/ml for BTV4 and
BTV16). The animals were observed for 30 days with daily
measurements of body temperature, and were evaluated for
clinical signs with a scoring system (Table 1). Vaccine immu-
nogenicity was evaluated by comparing the reactions of the
vaccinated and unvaccinated sheep to infectious challenge.
The control sheep should score at least 10 points after infec-
tion. A difference between the vaccinated and unvaccinated
sheep was considered insignificant if the average difference in
the scores was 0–7 points, weak if the difference was 7–12
points, moderate if the difference was 12–16 points, and pro-
nounced if the difference was >16 points (Sergeev et al. 1981).
Group-specific ELISAs
The BTV-specific antibodies in the sheep sera were detected
with a competitive ELISA (cELISA, ID-Screen Bluetongue
Early detection ELISA, ID-Vet, Montpellier, France) directed
against VP7, according to the manufacturer’s instructions. For
this study, a threshold value of 40 % negativity (PN) was used
to discriminate between positive (PN < 40) and negative
(PN ≥ 40) BTV ELISA results.
Detection of neutralizing antibody response in the sera
of vaccinated animals
SNT was performed according to the method of Haig and
MaRAA (1956) using the BTV-4 and BTV-16 reference strains
and serotype-specific BTV-4 and BTV-16-positive control
antisera. Briefly, the sheep sera were diluted (1:2 to 1:128)
and titrated against 100 TCID50 of the BTV-4 vaccine strain.
BTV16 was analyzed separately, in a similar way. The plates
were incubated for 1 h at 37 °C, and then maintained at 4 °C
overnight. The following day, 50 μL of a Vero cell suspension
(2 × 105 cells/mL) was added to each well, and the plates were
incubated for 4–7 days at 37 °C. The wells were then scored for
a cytopathic effect. The neutralization titer was determined as
the dilution of serum giving a 50 % neutralization end point.
Table 1 Assessment of clinical signs of bluetongue in sheep
Category Clinical sign Score
Fever (temperature 40.1 °C
and higher)
1–3 days with a peak of up to 41 °C 1
1–3 days with a peak greater than
41 °C
2
4 or more days with a peak of
up to 41 °C
3








Cervical swelling Mild swelling of the eyelids or lips 1




Erosion or hemorrhage Erosions in the oral and nasal
cavities or hemorrhages on the
nares or nasal planum
3
Keratitis Focal unilateral keratitis 2
Diffuse unilateral or multifocal
bilateral keratitis
3
Diffuse bilateral keratitis 4
Attitude Mildly depressed 1
Moderately depressed 2
Severely depressed with anorexia 3
Muscle weakness Mild 1




Nasal secretions Mucous 1
Purulent 2
Sialorrhea Sialorrhea or foaming at the mouth 1
Diarrhea 1
Body condition Decreased body condition 1
Emaciation 2
Maximum score 30
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Statistical analysis
All statistical analyses were performedwith GraphPad Prism®
version 6.0. Two-way analysis of variance was used to com-
pare the rectal temperatures, clinical scores, and serology of
the groups, with P ≤ 0.05 considered statistically significant.
Results
Safety of test series of the bivalent live cultural vaccine
against BTV
Other than a relatively mild fever (40.3–40.8 °C) for 2–4 days
and swelling at the site of vaccination which resolved within
2–3 days, the animals developed no clinical signs after vacci-
nation (Table 2). These results indicate that this vaccine is
generally safe for sheep.
Reversion to virulence
Both strains induced viremia in susceptible animals (Fig. 1).
During the passages in sheep, the BTV titer was 1.16 ± 0.16
log10 TCID50/mL at the first passage, decreasing to
0.83 ± 0.08 and 0.92 ± 0.08 log10 TCID50/mLwith subsequent
passages (P ≤ 0.001) (10 total).
The attenuated virus showed no pathogenic properties after
its intravenous administration to sheep, and all the animals
remained healthy during the observation period (30 days).
Neutralizing antibody titers
One week after vaccination, all the sheep had detectable levels
of neutralizing antibodies, measured with a SNT, with mean
titers (log10) ranging from 1.1 (for BTV-4) to 1.25 (for BTV-
16) at 7 days after-vaccination (Fig. 2). Four weeks after vac-
cination, all the vaccinated animals had even higher levels of
neutralizing antibodies: 4.0–4.8 log2 at 28 days and 1.8–2.0
log2 at 360 days (Fig. 2).
The levels of NA in the sera of the immunized sheep dif-
fered significantly for both serotypes from day 7 to day 360
(P ≤ 0.0001).
Group-specific antibody titers
A graphical summary of the percentage inhibition (IP)
results are given for each group in Fig. 3. All sheep
were seronegative before vaccination and the control
sheep remained seronegative in all assays until chal-
lenge. After vaccination, the percentage inhibition
Fig. 1 Viral titers during passage. We used 30 seronegative sheep in the
experiment. The sheep were divided into 10 groups of three animals. The
first group was administered the vaccine intravenously at a dose of 104
TCID50/mL. To determine the level of viremia 7–8 days after viral
inoculation, blood samples were collected from the febrile animals in
ethylenediaminetetraacetic acid and titrated in Vero cell culture. The
inoculum (10-mL) was administered to the second group of three
sheep. Further testing was performed similarly in triplicate after each of
the 10 passages
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Clinical signs or reaction of animals
Swelling Fever Stomatitis Diarrhea Conjunctivitis Nasal secretions Sialorrhea Depletion
Live attenuated
bivalent vaccine
134 1 × 106/1.0 + + − − − − − −
182 1 × 106/1.0 + − − − − − − −
163 1 × 106/1.0 + + − − − − − −
132 1 × 106/1.0 + + − − − − − −
336 1 × 106/1.0 + − − − − − − −
181 1 × 106/1.0 + + − − − − − −
178 1 × 106/1.0 + + − − − − − −
333 1 × 106/1.0 + − − − − − − −
192 1 × 106/1.0 + + − − − − − −
PBS (control) 398 0/1.0 + − − − − − − −
353 0/1.0 + − − − − − − −
decreased dramatically. The optical densities of specific anti-
bodies decreased throughout the duration of the study, from
IP < 8 ± 3.07 at day 28, to IP < 16.5 ± 4.95 at day 90, and
IP < 46.25 ± 6.40 at day 360.
Clinical protection following challenge
Seven days after immunization, the animals developed protec-
tive immunity against BTV (Fig. 4a). However, the vaccinated
animals were insufficiently protected from challenge because
they developed clinical signs of bluetongue, with an average
score of 10 points. The unvaccinated control animals also
developed clinical signs, with an average score of 20.8
points, so the difference in the mean scores was 10.8
points. At 14, 90, and 270 days after immunization,
strong protective responses developed against BTV-4
and BTV-16 (Fig. 4b, c). The vaccinated animals
showed a slight increase in body temperature after chal-
lenge, whereas the unvaccinated animals developed typ-
ical clinical signs of the disease. At 360 days after
immunization, one vaccinated sheep showed an increase
in body temperature of 41.5 °C for 2 days after chal-
lenge, which then returned to normal (Fig. 4d). The
vaccinated animals had an average clinical score of
one point after challenge, whereas the unvaccinated an-
imals had an average score of 27 points, indicating the
high protective activity of the test vaccine.
Discussion
Infection with BTV is common in a broad band across the
world, which until recently stretched from latitude ~35°S to
40–50°N. Since the 1990s, the range of BTV has extended
considerably north of the 40th and even the 50th paral-
lels in some parts of the world (Maan et al. 2007;
Coetzee et al. 2012).
All attenuated BTV strains have pronounced reactogenic
properties. These properties are characterized by the appearance
in the vaccinated animal of a quite moderate to severe reaction
temperature, between 6 and 10 days after vaccination. The re-
sponse to the vaccine is followed by viremia. These phenomena
are regarded as positive signs of infection, indicating the devel-
opment of an immune response (Kercher et al. 1957).
One of the most important steps when preparing a live-
attenuated vaccine is the assessment of its level of attenuation
in the target animals (sheep and newborn mice). These
models, which are used to evaluate the attenuation of BTV,
are sufficient to test the attenuated strains (Franchi et al. 2008).
Therefore, we determined the levels of attenuation of the BTV
strains with 10 serial passages in sheep. We evaluated the
reversion of the two vaccine strains by passaging them 10
times through susceptible sheep, and thus showed that the
pathogenicity of these attenuated strains was not restored.
However, these strains replicated in the sheep and could
be isolated from the blood of the animals 2–12 days
after vaccination.
Fig. 3 Evolution of mean
percentage inhibition s (with
standard deviation) in each group
of vaccinated and control sheep
during the experiment after a
single vaccination. (anti-VP7
antibody ELISA)
Fig. 2 Dynamics of neutralizing
antibodies in the vaccinated
sheep. Data are means ± standard
errors; ****Р < 0.0001.
Neutralizing antibody titers were
calculated with the Reed–Muench
method and are expressed as log2
values
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The MLV vaccine administered at doses not exceeding 2.0
log10 TCID50/mL, produced long-lasting viremia in the sheep,
whereas virulent strains accumulated in the blood at levels up
to 5.50 log10 TCID50/mL. Although this viremia makes the
MLV more immunogenic, because it continues to producing
an immune response long after the initial injection, the possi-
bility of reversion to virulence cannot be ruled out given the
limitations of the present study. In particular, previous re-
search has shown that the virus can revert to virulence after
infecting its natural vectors (Batten et al. 2008). In this case,
the viremia produced by the vaccine strain persisted longer
than that induced by the pathogenic strains. Vaccination with
MLVand inactivated viruses produces neutralizing and group-
specific antibodies (Oura et al. 2009; Hamers et al. 2009)
protecting the vaccinated animal against challenge. Live-
attenuated vaccines usually elicit a strong immune response,
with the development of antibodies, and are usually effica-
cious after a single dose (Patta et al. 2004; Dungu et al. 2008).
Neutralizing antibodies have been shown to be an essential
component of the protective immune response against BTV
(Huismans et al. 1987; Roy et al. 1990) and similar titers,
(1.5–2.5 log2) have been observed after vaccination with
killed commercial vaccines in ruminants, which were ulti-
mately protected from BTV-8 challenge (Bréard et al. 2011).
Our experimental data are consistent with those of other re-
searchers. Therefore, we have established that 7 days after
vaccination with the attenuated vaccine, virus-neutralizing an-
tibodies to BTV are present in the sera at a titers of 1.0 log2.
This antibody titer is protective against the homologous viru-
lent strain of BTV. Although further research isrequired, par-
ticularly regarding the safety of the vaccine in pregnant sheep,
this bivalent vaccine has been shown to be safe and effica-
cious, and will be a valuable tool in preventing the spread of
bluetongue to Kazakhstan.
Conclusions
In conclusion, in an efficacy study, a single dose of an atten-
uated bivalent vaccine directed against BTV-4 and BTV-16
provided solid clinical protection against experimental chal-
lenge for 12 months. There was a strong anamnestic response
in the vaccinated sheep and a good correlation between the
neutralizing antibodies at the time of challenge and the
protection afforded against both viral replication and clinical
disease.
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